Category Archives: Insights

zoom
diversity, workforce, immigration, millennials, donald trump, biotech, healthcare, technology, innovation
-

Why Diversity Is Essential

In President Donald Trump’s address to joint sessions of Congress, he announced the White House is planning to unveil a new executive order on immigration tailored to respond to recent court rulings. As you may know, federal judges put a hold on the President’s original executive order banning travelers from seven majority-Muslim countries to enter the US.

Continue reading

zoom
drug prices, medicine, prescription, Affordable Care Act, drug costs, healthcare costs, health
-

Reducing Drug Prices: A Look at Both Sides of the Issue

In December, the healthcare industry rejoiced as the 21st Century Cures Act achieved overwhelming bipartisan support in Congress and was signed into law by Former President Obama. The new legislation aims to increase funding for cancer research, speed the development and approval of new treatments, and strengthen mental health services.

Continue reading

zoom
fig2
-

ASCO 2015 Round-Up: Immunotherapy in the Spotlight

As June marks Cancer Immunotherapy Awareness Month, I wanted to reflect on some of the key scientific takeaways from the American Society of Clinical Oncology’s (ASCO) annual meeting, and how these advancements are shaping the future of immunotherapy and our work at OncoSec. After digesting the news and outcomes, I’ve summarized my personal highlights and research insights from the week.

Continue reading

zoom
Part-3-Image
-

Innovation Through An Academic Network: Part 3 The Future of Pharma

Looking ahead, our work is cut out for us in terms of R&D as many diseases and conditions are yet to be fully understood. By establishing partnerships with academia, we can further explore disease states, concentrate on early-stage molecule development, and optimize a product candidate. Not only is this relationship beneficial in terms of budgetary benefits (for both industry and academia), but it also increases engagement between pharma companies and the scientific community at large.

Continue reading

zoom
Part-2-Image
-

Innovation Through An Academic Network: Part 2 – Building New Channels to Advance Research

As we move into the Process Innovation era, new ways of developing more effective and safer treatments are required. In 2010, the number of drug approvals hit a record low, and several high profile molecules that had shown promise failed in the late stage of development. This was a huge loss for companies, who invested significant time, resources, and funds into the development of these molecules.

Continue reading

zoom
Part-1-Image
-

Innovation Through An Academic Network: Part 1 – The Evolution of the Pharmaceutical Landscape

Today, the pharma landscape is increasingly multifaceted, but it’s taken us a while to reach this moment in time. Fifteen years ago, the pharma landscape was centered on Product Performance: discovering or synthesizing molecules that deliver proven clinical results. Under this principle, sales reps marketed to and dealt directly with physicians, and there was little communication with or educational resources for consumers.

Continue reading

zoom
Grind for the Mind
-

Grind for the Mind

My family and close friends know how fanatical I can be about the Grouse Grind – simply if Vancouver could embody a prototypical stereotype, the “Grind” as more commonly referred to would be up there with running around Stanley Park in your Lululemon outfit. 

Continue reading